Rezolute Reports Positive Interim Phase 3 upLIFT Data, 6 of 8 Patients Meet Primary Endpoint

What happened

Rezolute announced that its Phase 3 upLIFT study in tumor hyperinsulinism is now 50% enrolled, with 6 of 8 evaluable patients already meeting the responder criterion for the primary endpoint. This open-label, single-arm trial aims for topline results in the second half of 2026, and the early signal supports the mechanistic rationale for ersodetug in this ultra-rare indication. However, the dataset remains very small and uncontrolled, and the company’s congenital hyperinsulinism program was recently dealt a severe blow with the failed sunRIZE trial. Despite the positive interim update, Rezolute remains a binary, cash-burning entity with a high-risk profile and an enterprise value heavily dependent on these tumor HI results. Investors should view this as an incremental positive that does not resolve the fundamental uncertainty around regulatory and commercial success.

Implication

The interim data is a modest de-risking event for the upLIFT program, potentially increasing the probability of a successful topline readout in 2H26. However, the stock still trades at ~$2.70 with ~$168M cash, implying a low enterprise value that partially discounts the tumor HI opportunity. The key catalysts remain FDA feedback on congenital HI and the upLIFT topline; until then, the thesis is still dominated by binary outcomes and legal overhang. A disciplined investor should await a clearer risk-reward entry point, such as a pullback after this news or confirmation of FDA alignment on congenital salvage. The base case of ~$4.00 per share in the DeepValue report now seems slightly more achievable, but the bear case of $1.25 remains plausible if upLIFT fails.

Thesis delta

The positive interim upLIFT data modestly increases the probability of the base case scenario (40% probability) while leaving the bear and bull scenarios largely unchanged. Investors should not overreact to this early signal; the fundamental investment thesis remains one of watching and waiting for clearer regulatory and clinical milestones. The stock’s recent insider buying and the interim data create a slightly more favorable asymmetry, but conviction to initiate a position is still lacking.